Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Rio de Janeiro, Brazilië, 20211-030
- Novo Nordisk Investigational Site
-
-
Parana
-
Curitiba, Parana, Brazilië, 80250-060
- Novo Nordisk Investigational Site
-
-
Sao Paulo
-
Campinas, Sao Paulo, Brazilië, 13081970
- Novo Nordisk Investigational Site
-
São Paulo, Sao Paulo, Brazilië, 05403-000
- Novo Nordisk Investigational Site
-
-
-
-
-
Milano, Italië, 20124
- Novo Nordisk Investigational Site
-
-
-
-
-
Shizuoka-shi, Shizuoka, Japan, 4208660
- Novo Nordisk Investigational Site
-
-
-
-
-
Adana, Kalkoen, 01130
- Novo Nordisk Investigational Site
-
Antalya, Kalkoen, 01010
- Novo Nordisk Investigational Site
-
Bornova-IZMIR, Kalkoen, 35100
- Novo Nordisk Investigational Site
-
Izmit, Kalkoen, 41380
- Novo Nordisk Investigational Site
-
-
-
-
-
Vilnius, Litouwen, LT-08406
- Novo Nordisk Investigational Site
-
-
-
-
-
Skopje, Macedonië, de Voormalige Joegoslavische Republiek, 1000
- Novo Nordisk Investigational Site
-
-
-
-
-
Kuala Lumpur, Maleisië, 50400
- Novo Nordisk Investigational Site
-
-
-
-
-
Warszawa, Polen, 00-576
- Novo Nordisk Investigational Site
-
Wroclaw, Polen, 50-345
- Novo Nordisk Investigational Site
-
-
-
-
-
San Juan, Puerto Rico, 00935
- Novo Nordisk Investigational Site
-
-
-
-
-
Moscow, Russische Federatie, 105077
- Novo Nordisk Investigational Site
-
Saint-Petersburg, Russische Federatie, 191119
- Novo Nordisk Investigational Site
-
-
-
-
-
Belgrade, Servië, 11000
- Novo Nordisk Investigational Site
-
-
-
-
-
Taipei, Taiwan, 40447
- Novo Nordisk Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85016-7710
- Novo Nordisk Investigational Site
-
-
California
-
Orange, California, Verenigde Staten, 92868
- Novo Nordisk Investigational Site
-
Torrance, California, Verenigde Staten, 90502-2004
- Novo Nordisk Investigational Site
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33607
- Novo Nordisk Investigational Site
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Novo Nordisk Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Novo Nordisk Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Novo Nordisk Investigational Site
-
East Lansing, Michigan, Verenigde Staten, 48823
- Novo Nordisk Investigational Site
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108-4619
- Novo Nordisk Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198-2168
- Novo Nordisk Investigational Site
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11201-5425
- Novo Nordisk Investigational Site
-
Valhalla, New York, Verenigde Staten, 10595
- Novo Nordisk Investigational Site
-
-
Ohio
-
Dayton, Ohio, Verenigde Staten, 45404
- Novo Nordisk Investigational Site
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239-3098
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Novo Nordisk Investigational Site
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Novo Nordisk Investigational Site
-
Houston, Texas, Verenigde Staten, 77030
- Novo Nordisk Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A
- Age below 12 years and weight at least 11 kg
Exclusion Criteria:
- Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)
- Congenital or acquired coagulation disorders other than haemophilia A
- Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: rFVIII
|
Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))
Tijdsspanne: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
The incidence rate of FVIII inhibitors was calculated by including all patients with inhibitors in the nominator and including all patients with a minimum 50 exposure plus any patients with less than 50 exposures but with inhibitors in denominator.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of Adverse Events (AEs)
Tijdsspanne: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Adverse event was defined as events occurring after administration of trial product.
Severe AEs: considerable interference with subject's daily activities, unacceptable.
Moderate AEs: Marked symptoms, moderate interference with the patient's daily activities.
Mild AEs: No or transient symptoms, no interference with the patient's daily activities.
Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, Kilinc Y, Amit Y, Amendola A, Solimeno LP, Saugstrup T, Matytsina I. Safety and efficacy of turoctocog alfa (NovoEight(R)) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia. 2015 Jan;21(1):34-40. doi: 10.1111/hae.12518. Epub 2014 Oct 2.
- Ozelo MC. Updates from guardian: a comprehensive registration programme. Eur J Haematol. 2015 Dec;95 Suppl 81:22-9. doi: 10.1111/ejh.12648.
- Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013 Sep;19(5):698-705. doi: 10.1111/hae.12165. Epub 2013 May 8.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- NN7008-3545
- U1111-1113-7182 (Andere identificatie: WHO)
- 2009-016383-36 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .